CSL-Novartis deal includes US cell-based flu vaccine plant

Robert Roos | News Editor | CIDRAP NewsOct 27, 2014The $375 million deal will make the company the second leading player in the $4 billion global flu vaccine market.Share Tweet LinkedIn Email Print & PDF
Oct 27, 2014

The $375 million deal will make the company the second leading player in the $4 billion global flu vaccine market.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest